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Abstract
Routinely collected electronic health records (EHRs) are increasingly used for research. With their use comes the opportunity for
large-scale, high-quality studies that can address questions not easily answered by randomised clinical trials or classical cohort
studies involving bespoke data collection. However, the use of EHRs generates challenges in terms of ensuring methodological
rigour, a potential problem when studying complex chronic diseases such as diabetes. This review describes the promises and
potential of EHRs in the context of diabetes research and outlines key areas for caution with examples. We consider the
difficulties in identifying and classifying diabetes patients, in distinguishing between prevalent and incident cases and in dealing
with the complexities of diabetes progression and treatment. We also discuss the dangers of introducing time-related biases and
describe the problems of inconsistent data recording, missing data and confounding. Throughout, we provide practical recom-
mendations for good practice in conducting EHR studies and interpreting their results.
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CKD Chronic kidney disease
CVD Cardiovascular disease
EHR Electronic health record
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Introduction
A greater understanding of the changing patterns of treatment,
patient demographics, risk factors and disease burden is vital
to inform clinical care and public health policy in diabetes.
RCTs are key but will not answer all questions as they have
several limitations: (1) they often have insufficient power and
length of follow-up to examine clinical endpoints; (2) aspects
of patient behaviour and clinical care are likely to differ in
trials compared with real-world settings and (3) important
groups, such as women of childbearing age, individuals with
multimorbidities and ethnic minorities, may be under-
represented in clinical trial populations [1–3]. On the other
hand, classical cohort studies involving bespoke data collec-
tion are expensive and time consuming and rarely have long-
term follow-up for participants beyond the initial study period.
The use of electronic health records (EHRs) for research
allows us to overcome many of these limitations and address
important scientific questions. Post marketing and surveil-
lance studies using EHRs are key for speeding up access
to new drugs [4]. Recognising this, the ADA recently en-
dorsed the use of evidence from high-quality observational
studies to aid therapeutic decision making [5, 6]. In recent
years, the use of EHRs for research has grown tremendously
and the potential for observational studies using EHRs to
generate valid estimates of causal associations is beginning
to be explored. Though EHRs have the potential to produce
high-quality research, major challenges exist. In this narra-
tive review, we describe the promises and potential of EHRs,
outline some key areas of caution and provide practical rec-
ommendations for using EHRs in the context of diabetes
research.
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The promise of EHR data
The term ‘electronic health record’ encompasses a wide vari-
ety of data sources including, but not limited to, routinely
collected primary and secondary care records, disease-
specific registries and health insurance claims databases
(Table 1). Several key potential advantages of EHRs are
outlined in the text box below.
EHRs are widely used to enable contemporary estimation
of disease incidence or prevalence [13–15], study prospective
associations between risk factors and disease outcomes [16],
establish trends over time [17] and model the best use of
healthcare resources [18, 19]. Importantly, many EHRs also
provide high-quality data onmedication prescribing. In claims
databases, any medication claimed for under a health insur-
ance policy is typically recorded by the insurance provider. In
primary care databases, information on medications pre-
scribed by the general practitioner (GP), such as number of
tablets and dosage, are recorded, while in pharmacy databases,
data on dispensing of medications are also available.
Traditionally, data from EHRs have been used to assess ad-
verse effects of treatment, especially unexpected effects.
Improvements in the availability and quality of data and ad-
vances in study designs and analytical methods have broad-
ened the value of such studies. This enables researchers to
answer questions of both regulatory and epidemiological im-
portance more quickly than with traditional study designs
where data are collected in real time after conception of the
study. EHRs have already been used to answer a range of
questions concerning diabetes risk and treatment effects [20,
21].
Although no one database is likely to have a complete
picture of an individual’s medical history, linkage between
EHRs can improve completeness and validity of key mor-
bidity data, as demonstrated for myocardial infarction [22],
and enable the study of exposures and outcomes which
would otherwise be impossible in unlinked data. In the
UK, primary care data are routinely linked to Office for
National Statistics death certificate data (providing de-
tailed information on causes of death), hospital data (pro-
viding information on diagnoses from secondary care),
deprivation data and disease-specific registries (e.g. for
cancer and acute coronary syndromes) [12]. Similar link-
ages are also available between databases in the USA [23].
The availability of linked data depends greatly on the data
provider, data infrastructure and, in the USA, healthcare
provider. In Denmark and other Scandinavian countries,
however, information across a wide range of databases
(such as hospital records [11], prescriptions [24] and dis-
ease registries [25]) are all linked by a unique identity code
assigned to each resident either at birth or when they be-
come a resident [6], resulting in virtually complete popu-
lation coverage and linkage. Linkages to biobanks can also
provide highly detailed information on laboratory results
and genetic markers (see for example http://www.bbmri-
eric.eu/, accessed 5 June 2017); [26, 27]. Further,
although different EHRs may use differing classifications
and coding systems (e.g. Read codes vs ICD), combining
data from multiple sources is still possible since mappings
between coding and classification systems are generally
available, or may be done on a study by study basis.
Possible pitfalls of EHRs
We summarise a broad range of issues relevant to the study of
diabetes using EHRs. A previous systematic review has de-
tailed the methodological challenges of studying glucose-
lowering medications in observational studies [28].
Therefore, issues specific to the study of drug effects, such
as confounding by indication (whereby the reason for being
prescribed [or not prescribed] the drug is itself related to the
risk of the outcome), are not covered here.
Accurate identification of diabetes status
Accurate disease ascertainment and categorisation is an essen-
tial first step towards identifying patterns of disease, and
• Studies are cost effective to conduct as data are 
already collected for other purposes
• Data are not affected by recall bias as they are 
collected prospectively in real time
• Data are available in near-real time, vital for a 
fast-changing field such as diabetes
• Large sample sizes allow for increased power to 
conduct granular comparisons between population 
subgroups and to investigate rare outcomes [7, 8]
• High validity of coded data for many diagnoses 
[9–11]
• Detailed prescribing and dispensing information 
often available for medications 
• Potential for linkage across a range of healthcare 
settings
• Samples often representative of the source 
population, allowing for accurate generalisations [6, 
12]
Advantages of research using EHRs
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targeting interventions and resources appropriately.
Challenges for diabetes researchers include the long latency
between disease onset and diagnosis, and misclassification of
diabetes type (e.g. older-onset type 1 diabetes being
misclassified as type 2). Such misclassification may result in
a biased estimation of the impact of diabetes on outcomes.
Medication records may be used to supplement clinical data
in identifying individuals with diabetes but this can present
additional problems (e.g. metformin is used for the treatment
of polycystic ovary syndrome and insulin is used in both type
1 and type 2 diabetes). Algorithms combining both diagnostic
and supporting information (e.g. medication, laboratory re-
sults, age, BMI) have been developed to overcome these chal-
lenges [14, 29].
Differentiating between prevalent vs incident disease
and treatment
In many EHRs, individuals often join the database at time
points with no clear clinical significance. For example, in pri-
mary care records, the first database entry is made on the date of
an individual’s initial registration with the GP. At the initial
visit, a GP may enter details for all pre-existing conditions.
Therefore, in the period immediately after an individual enters
the database, it may be unclear whether a new diabetes diag-
nostic code reflects existing diabetes or a new diagnosis [30].
This may limit the ability to adjust for diabetes duration, which
may be an important source of confounding, particularly in
studies comparing diabetes treatments. It is also typically un-
clear whether a new medication record in this early period
reflects continuation of an existing therapy or incident use.
Including prevalent users in a study of drug effects can lead
to serious bias if treatment effects or risks vary over time, as is
often (although not always) the case in diabetes. This is because
prevalent users will have already ‘survived’ the early period of
therapy [31]. For this reason, so-called new-user designs are
generally encouraged, wherein new drug users are typically
identified by requiring a certain period (e.g. 12 months) of
follow-up before the first prescription [32]. However, it should
be acknowledged that such designs may come at the price of
loss in power, since we often reduce the sample to individuals
with shorter exposure or duration of disease, which may reduce
the number of long-term outcomes observed.
Use of future information
When an EHR study is designed, it is often the case that all, or a
large proportion, of the follow-up information is already
Table 1 Examples of EHRs
EHR Data types available Examples
Primary care databases Diagnoses of chronic and acute conditions, prescription data,
information on processes of care procedures and monitoring
(e.g. blood tests, BP, screening and annual health checks),
as well as demographic and lifestyle information such as
age, sex, smoking and alcohol consumption
Clinical Practice Research Datalink (UK)
QRESEARCH (UK)
SAIL database (Wales)
Primary Care Sentinel Surveillance Network (Canada)
Integrated Primary Care Information Database (Netherlands)
The Information System for the Development of Research
in Primary Care (Spain)
Secondary care
databases
Admissions to inpatient, outpatient and emergency services,
diagnostic and procedural codes and administrative
information such as length of stay, ward and specialty area
Hospital Episode Statistics (UK)
National Registry of Patients (Denmark)
Disease registries Detailed information on the relevant condition (e.g. cancer
registries have details of date of diagnosis, cancer type,
grade and treatments received but may lack information
on comorbidities and concomitant medication)
Primary Care Cardiovascular Database (Sweden)
Global Rare Diseases Patient Registry Data Repository (USA)
Myocardial Ischaemia National Audit Project (UK)
Danish Huntington Register (Denmark)
Insurance claims
databases
Demographic information on the individual enrolled in the
insurance plan, as well as details of medical history that
have been covered and medication that has been claimed
for under the insurance plan (e.g. information on
prescription drugs and hospital inpatient and outpatient care)
Medicare (US)
Health Maintenance Organizations (HMOs) such as
Molina Healthcare, Kaiser Permanente, United
Healthcare (USA)
National Health Insurance Research Database (Taiwan)
PHARM (Italy)
Pharmacy databases Drug dispensing, effectiveness, safety and cost data Scottish National Prescribing System (Scotland)
PHARMO database (Netherlands)
Deutsches Arzneiprüfungsinstitut
(Germany)
Regulatory databases Spontaneous reports of adverse drug reactions (ADRs) Vigibase (WHO spontaneous reports database)
EudraVigilance (Europe)
GECEM (France)
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available. Using future information when defining cohort in-
clusion, exposure status or covariate values at the time of study
entry risks biasing the results because patient outcomes have
influenced how they are dealt with in the study prior to their
outcome [33]. As a simple example, consider a study of BMI
and future risk of cardiovascular risk using a diabetes registry.
Each individual may have multiple measures of BMI from the
time they enter the registry until the time they exit the database
or develop cardiovascular disease (CVD). If all BMI measures
are used to determine whether an individual is overweight at
study entry (e.g. by calculating an average BMI over follow-
up), then the target comparison of ‘overweight’ vs ‘normal
weight’ becomes a comparison of ‘average overweight’ vs ‘av-
erage normal weight’, leading to unclear interpretation and po-
tential selection bias. An average normal weight could mask
weight loss as a consequence of undiagnosed CVD, or a CVD
diagnosis that appears late in the course of disease. Another
problem of using future information is that concerning ‘immor-
tal time bias’. This term is associated with the concept that
during certain time periods during follow-up, a specific out-
come cannot occur. Levesque et al [34] demonstrated this using
data from a Canadian health database: they defined statin users
as those with 12 or more months of continuous use during
follow-up, and compared rates of insulin initiation (a proxy
for diabetes progression) from study entry between users and
non-users. This led to an estimated protective effect of statins.
The problemwith this approach is that anyone experiencing the
outcome (insulin initiation) before completing 12 months of
statin use would be classified as a non-user as their time at risk
in the study would end at this point so they could not fulfil the
definition of being a statin user. The corollary to this is that
those categorised as statin users could not by definition have
experienced the outcome (insulin initiation) prior to starting a
statin and completing 12 months of statin use, creating a period
of ‘immortal time’ for statin users. When this event-free per-
son-time is included in the denominator, outcome rates in the
exposed group are biased downwards, leading to an overall
bias towards a protective effect of exposure. When the authors
instead used a correct time-updated approach wherein an indi-
vidual’s exposure status was updated from non-user to user
once that individual reached 1 year from their first statin pre-
scription, the protective effect of statins disappeared. Another
solution might have been to start follow-up 1 year after the first
statin prescription for statin users and to use a matched date for
non-statin-users. Immortal time bias, along with other time-
related biases, has been previously described in reference to
studies of metformin and cancer risk in patients with diabetes
[35] and in the previously referenced review by Patorno et al
[28].When defining inclusion criteria and exposures/covariates
intended to reflect the point of study entry, it is worth asking the
question ‘Have I only used information that I would have had at
the time of recruitment had I conducted this study in real time?’
If the answer is no, then bias may inadvertently be introduced.
Dealing with the complexities of diabetes progression
One of the most common scenarios in which bias from use of
future information manifests in diabetes epidemiology is
when dealing with treatment switches over the course of fol-
low-up. Studies may restrict the study population to individ-
uals who remain on a single therapy regime throughout fol-
low-up, leading to selection bias or immortal time. One solu-
tion is to model the treatment of interest as time-varying, thus
allowing the inclusion of all patients by accounting for their
treatment modality. Such a solution would be relevant to the
study of any exposure (e.g. BMI, HbA1c, eGFR) that changes
as the disease progresses. Although an important advantage of
EHRs is the ability to collect longitudinal data to investigate
such time-varying exposures, dealing with confounding in-
variably becomes more complex in this situation. When con-
sidering how to model changes in exposure status through
time, one must determine first whether information on time-
varying confounders (confounders of the association between
exposure and outcome that also change through time) is avail-
able in the database and second whether the time-varying
confounders may also be affected by prior exposure status.
If time-varying confounding is thought to be present, then
adjustment for the value of the confounder at study entry only
may not remove confounding for those whose exposure status
changes over the course of follow-up. This can be overcome
by using methods such as time-varying Cox proportional haz-
ards models, which time-update the value of the confounder as
it changes. However, if prior exposure is expected to affect
future values of the confounder, then this method may not be
appropriate as the adjustment may remove the effect of treat-
ment that acts via future values of the confounder. These lim-
itations of standard analysis methods in the presence of time-
dependent confounders affected by prior exposures for diabe-
tes research have been described in more detail in a systematic
review [36], and more generally elsewhere [37]. Such issues
occur both when examining time-varying treatment and time-
varying risk factors such as BMI or glucose control or pro-
gressive conditions such as chronic kidney disease (CKD).
For example, if we wish to examine the effect of CKD stage
on mortality in individuals with diabetes, then HbA1c may be
a time-varying confounder of the association but CKD stage
may also influence future HbA1c. Methodological approaches
to dealing with time-varying confounders affected by prior
treatment include inverse probability weighting of marginal
structural models, g-computation and g-estimation [38]. In
theory, these methods correctly adjust for the time-varying
confounding without losing any effect of exposure that acts
via future values of the confounder, subject to certain assump-
tions [38]. If such methodologies are not feasible, simpler
study designs in which exposures are assumed to remain fixed
from study entry (analogous to intention to treat analyses) may
still be used to examine exposure/outcome associations but
Diabetologia
such designs can only answer more limited questions that
ignore the reality of individuals changing treatments over
time.
Finally, another consideration when dealing with time-
varying exposure, is the extent to which changes in exposure
are a result of reverse causality. For instance, many people
lose weight shortly before diagnosis of diabetes, due to under-
lying ill health. Using weight measures shortly before diagno-
sis may lead to the erroneous conclusion that low weight is a
risk factor for diabetes. It is advisable to conduct a sensitivity
analysis to determine whether this may be an issue (e.g. by
defining the date of exposure as being 6–12 months after the
date observed within the EHR) [30].
Context in which data are collected
Understanding the purpose for which the data were initially
collected andmethods of data collection are critical to accurate
analysis and interpretation of EHR research and for assessing
the likelihood of encountering problems of missing data and
unmeasured confounding.
Selection biases arising from data availability Primary and
secondary care data are collected as and when individuals visit
their GP or hospital and therefore samples from these data-
bases may over-represent less-healthy individuals. This may
present less of a problem in studies restricted to individuals
with diabetes, since they will likely visit the GP on a semi-
regular basis and thus have similar amounts and types of data
recorded. However, if a general population comparison group
is selected, those with available data may not be representative
of the broader population. Even among individuals who do
visit their GP regularly, there may be less data collected on
those who are perceived to be healthier or at lower risk, as GPs
are less likely to perform routine investigations in this group.
Different considerations apply for claims databases: these may
have an over-representation of healthier individuals, as those
with pre-existing conditionsmay find it harder to receive med-
ical cover.
Missing data EHR data, for the reasons outlined above,
likely suffer from missing data issues. Often, we classify
variables based on the presence or absence of codes. For
example, when determining whether an individual has had
a previous CVD event, the presence of a code will indi-
cate ‘yes’, while the absence of a code will likely indicate
‘no’, and thus we can derive a CVD status for 100% of
individuals (albeit with the possibility of misclassifica-
tion). However, for measures such as blood pressure or
HbA1c, missing data are likely to indicate that the value
has not been recorded. Analysing only the subset of indi-
viduals that have complete data on all necessary covari-
ates is a commonly used approach but whether or not this
is reasonable depends on how the missingness is associ-
ated with the outcome of interest [39]. Advanced methods
such as multiple imputation may be used to assess the
extent to which missing data may affect the analysis and
to obtain more valid estimates of association if data are
missing at random, meaning that the reason for
missingness is independent of the value after conditioning
on other measured covariates [40]. Unfortunately, this is
an untestable assumption [40, 41] and often unlikely to
hold. For example, smoking is more likely to be recorded
in routine primary care among smokers, and BMI is more
likely to be recorded among overweight individuals.
Therefore, sensitivity analysis is always advisable and
there exist comprehensive practical guides to approaching
analysis with missing data [42, 43]. Even if observed, data
on behaviours such as smoking and alcohol consumption
are unlikely to be recorded with perfect accuracy, partic-
ularly since they are often self-reported and are subject to
social desirability bias [44].
Unmeasured confounding EHRs rarely contain information
on diet and physical activity, which may be important con-
founders when looking at diabetes-related exposures and out-
comes. Linkage to other sources may overcome this issue in
some situations (e.g. some biobanks collect cross-sectional
information on dietary intake). In some cases, proxies may
allow some degree of adjustment for unobserved variables.
For example, statin use may be a reasonable proxy for high
cholesterol where actual cholesterol values are not recorded. If
such options are not available, a negative control can be an
informative way of investigating the impact of unmeasured
confounding [45]. This involves examining an association that
could plausibly be affected by the same unmeasured con-
founders as the primary association of interest, but where the
true association is expected to be null. If the result obtained is
close to the expected null association, this provides reassur-
ance that unmeasured confounding is unlikely to be substan-
tially biasing the results of the primary analysis. Such a meth-
od has been successfully employed by Jackson et al in debates
over influenza vaccinations [46]. The authors estimated a pro-
tective association between vaccine use and trauma
hospitalisation, suggesting that unmeasured confounding
may be responsible for the observed reduction in respiratory
hospitalisation.
Recommendations
Although the challenges discussed in this paper were not iden-
tified systematically and were not intended to form an exhaus-
tive list, they lead us to outline some key recommendations for
best practice when studying diabetes using EHRs, as
displayed in the following text box.
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Conclusions
EHRs offer great potential for the study of complex
questions beyond the scope of traditional clinical and
observational studies due to the breadth and timeliness
of available data and the ability for linkage to secondary
care, mortality data and disease registries. As such,
there is a great opportunity to allow for more accurate
characterisation of diabetes type, progression of disease
and quality of care.
The increasing quantity and quality of computerised
health-related data offers exciting opportunities for re-
search in diabetes. However, the danger of poor quality
research with misleading results is high and could re-
sult in deleterious effects on patient care and on pre-
scribing. Improvements in reporting of research, driven
by initiatives such as the Reporting of Studies
Conducted using Observational Routinely Collected
Health Data (RECORD) reporting guidelines statement,
may make it easier to identify the most rigorous and
reliable research [47]. Further, sharing of code lists and
statistical code may improve reproducibility of research
using EHRs. Alongside these improvements in transpar-
ent reporting, increasing awareness of the methodolog-
ical challenges, such as those outlined in this paper, is
needed to help ensure that studies based on EHR data
produce valid results that usefully add to the evidence
base.
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